Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SBBP

Strongbridge Biopharma (SBBP) Stock Price, News & Analysis

Strongbridge Biopharma logo

About Strongbridge Biopharma Stock (NASDAQ:SBBP)

Advanced Chart

Key Stats

Today's Range
$1.95
$2.06
50-Day Range
$1.89
$2.29
52-Week Range
$1.85
$4.26
Volume
684,684 shs
Average Volume
866,464 shs
Market Capitalization
$135.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Receive SBBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBBP Stock News Headlines

Matinas BioPharma Holdings Inc (MTNB)
Lytix Biopharma As Share Price (LYTIX.OL)
Unlock the Secret to Microsoft's Yearly Gains
What would you do if you knew that you could have placed a trade on Microsoft every year on October 13th … And had the chance to pocket an impressive gain in a matter of days… And this didn’t work just once… Not twice… But it worked for an entire decade… According to market veteran Jack Carter’s research, the recurring phenomenon generated winner after winner for 10 straight years! All you had to do is wait for October 13th to roll around on the calendar… Then place a quick trade… Of course, we can’t promise profits or prevent losses… But you can get 10 FREE trade ideas from Jack, just like that one on Microsoft.
Ambrx Biopharma Inc AMAM
HILS Hillstream BioPharma, Inc.
ABUS - Arbutus Biopharma Corporation
See More Headlines

SBBP Stock Analysis - Frequently Asked Questions

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analyst estimates of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Strongbridge Biopharma investors own include Energy Transfer (ET), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
8/05/2021
Today
1/15/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBBP
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

Net Income
$-45,080,000.00
Net Margins
-115.67%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$30.73 million
Book Value
$0.98 per share

Miscellaneous

Free Float
N/A
Market Cap
$135.66 million
Optionable
Optionable
Beta
1.58

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:SBBP) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners